Paclitaxel-Induced Src Activation Is Inhibited by Dasatinib Treatment, Independently of Cancer Stem Cell Properties, in a Mouse Model of Ovarian Cancer.

Cancers (Basel) · 2019 · PMC6406511 · PMID 30791462

Europe PMC DOI

hedged sentence

—

closest p

—

boldest claim

The sentences

an increasing trendno p-value reported

The expression of SSEA-4 and CD44 had an increasing trend with paclitaxel treatment in TOV-21G cells, which was decreased by Dasatinib without significance. 2.5.

also in 63,971 other papers

Quoted from the open-access full text in Europe PMC under the licence the publisher applied. The sentence is reproduced exactly as published; the emphasis is ours.